Literature DB >> 8458455

Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome.

T D Pache1, F H de Jong, W C Hop, B C Fauser.   

Abstract

OBJECTIVE: To determine whether ovarian polycystic changes estimated by transvaginal sonography correlate with clinical and endocrine findings associated with the polycystic ovarian syndrome.
DESIGN: Prospective study.
SETTING: Reproductive Endocrinology Unit in the Department of Obstetrics and Gynecology at a teaching hospital. PARTICIPANTS: Ninety-five consecutive patients suffering from oligoamenorrhea entering an infertility treatment program.
INTERVENTIONS: All women were examined by transvaginal sonography, assessed for body mass index and hirsutism. Blood withdrawal was performed for hormone estimates. MAIN OUTCOME MEASURES: Ovarian follicle number, volume, and stroma echogenicity. Estimates of immunoreactive and bioactive luteinizing hormone (LH), testosterone (T), free T, insulin levels, and insulin resistance index were performed.
RESULTS: Hirsutism was present in 63% of the patients and correlated with the number of follicles, ovarian volume, and stroma echogenicity. Follicle number, ovarian volume, and stroma echogenicity values were significantly correlated with immunoreactive LH, bioactive LH, and T levels. Both T and immunoreactive LH were independently correlated with ovarian structure sonography parameters. Insulin and insulin resistance correlated with ovarian volume and stroma echogenicity. Insulin resistance was of significant additional predictive value of ovarian volume and amount of stroma. Evaluating the predictive value of immunoreactive LH and T together in regard to all sonography parameters, only T levels were statistically significant predictors of increase in follicle number, ovarian volume, and stroma amount.
CONCLUSIONS: Although immunoreactive LH and bioactive LH correlated with all ovarian parameters, the effect of androgens on ovarian changes appeared to be independent from LH. This further substantiates the apparent cardinal role of androgens in the genesis of polycystic ovaries. Besides, transvaginal sonography assessment of ovaries is a valuable additional tool for the diagnosis of PCOS. In this regard, insulin resistance is of additional predictive value for ovarian volume and stroma echogenicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458455     DOI: 10.1016/s0015-0282(16)55797-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Management of involuntary childlessness.

Authors:  W Himmel; E Ittner; M M Kochen; H W Michelmann; B Hinney; M Reuter; M Kallerhoff; R H Ringert
Journal:  Br J Gen Pract       Date:  1997-02       Impact factor: 5.386

2.  Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.

Authors:  Sarantis Livadas; Christos Pappas; Athanasios Karachalios; Evangelos Marinakis; Nikoleta Tolia; Maria Drakou; Philippos Kaldrymides; Dimitrios Panidis; Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2014-04-22       Impact factor: 3.633

Review 3.  Diagnostic criteria for polycystic ovarian syndrome.

Authors:  F J Broekmans; B C J M Fauser
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS).

Authors:  Jacob P Christ; Tommaso Falcone
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

5.  Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin.

Authors:  Angela Falbo; Morena Rocca; Tiziana Russo; Antonietta D'Ettore; Achille Tolino; Fulvio Zullo; Francesco Orio; Stefano Palomba
Journal:  J Ovarian Res       Date:  2010-07-21       Impact factor: 4.234

6.  The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: evidence from a large multicenter study in Spain.

Authors:  J Balasch; R Tur; P Alvarez; J M Bajo; E Bosch; I Bruna; P Caballero; J Calaf; I Cano; E Carrillo; J A Duque; G Folguera; A de la Fuente; C Jiménez; G Laguens; E López; A Lozano; A Matarranz; C Moreno; J Nava; M Sanchis; E Temprano; G Ventura; J A Peinado
Journal:  J Assist Reprod Genet       Date:  1996-08       Impact factor: 3.412

Review 7.  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.

Authors:  Niki Katsiki; Eleni Georgiadou; Apostolos I Hatzitolios
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

8.  The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women.

Authors:  Leif Bungum; Florencia Franssohn; Mona Bungum; Peter Humaidan; Aleksander Giwercman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.